- Home
- LFS vs MIST Comparison
LFS vs MIST Comparison
Compare LFS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | MIST |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Japan | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 163.2M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | LFS | MIST |
|---|---|---|
| Price | $4.05 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 2.6M | ★ 5.3M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.16 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $76,556,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.06 | ★ N/A |
| Revenue Growth | ★ 12.13 | N/A |
| 52 Week Low | $1.58 | $0.63 |
| 52 Week High | $12.49 | $3.06 |
Technical Indicators
Market Signals| Indicator | LFS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.58 |
| Support Level | N/A | $2.50 |
| Resistance Level | N/A | $2.73 |
| Average True Range (ATR) | 0.00 | 0.26 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 48.62 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).